These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25179937)

  • 1. Reply to Marc Bjurlin, Elena Elkin, and William Huang's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-41.
    Sun M; Karakiewicz PI
    Eur Urol; 2015 Apr; 67(4):e72. PubMed ID: 25179937
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Sun M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-41.
    Bjurlin M; Elkin EB; Huang WC
    Eur Urol; 2015 Apr; 67(4):e71. PubMed ID: 25179936
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Patel HD; Allaf ME
    Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management.
    Laguna MP
    J Urol; 2014 May; 191(5):1262-3. PubMed ID: 24745480
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management.
    Sun M; Becker A; Tian Z; Roghmann F; Abdollah F; Larouche A; Karakiewicz PI; Trinh QD
    Eur Urol; 2014 Jan; 65(1):235-41. PubMed ID: 23567066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Maxine Sun, Quoc-dien Trinh, Marco Bianchi, et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol 2012;61:725-31.
    Sandhu GS; Tanagho YS; Bhayani SB
    Eur Urol; 2012 Sep; 62(3):e58; author reply e59-60. PubMed ID: 22704368
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumas' Letter to the editor Re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol 2012;62:696-703.
    Sun M; Bianchi M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 May; 63(5):e65-6. PubMed ID: 23395592
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
    Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
    Eur Urol; 2015 Oct; 68(4):e84-5. PubMed ID: 26058957
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Maxine Sun, Lorenzo Marconi, Tim Eisen, et al. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol 2018;74:611-20: Systematic Review Findings on the Role of Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma.
    Hwang EC; Risk MC; Dahm P
    Eur Urol; 2019 Mar; 75(3):e67-e68. PubMed ID: 30466889
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
    Santoni M; Montironi R; Battelli N; Massari F
    Eur Urol; 2019 Mar; 75(3):e64-e66. PubMed ID: 30391082
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Maxine G. Tran, Ravi Barod, and Axel Bex's Letter to the Editor re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, et al. Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. Eur Urol 2019;75:861-7.
    Macklin PS; Sullivan ME; Tapping CR; Webster GM; Roberts ISD; Verrill CL; Browning L
    Eur Urol; 2019 Jun; 75(6):e177-e178. PubMed ID: 30827695
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to M.V. Meng's Letter to the Editor re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9 and P.L. Steinberg et al. re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9. Eur Urol 2007;51:572-3.
    O'Kane HF; Nambirajan T
    Eur Urol; 2007 May; 51(5):1449. PubMed ID: 17229516
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Aaron M. Potretzke, Jeffrey A. Larson and Sam B. Bhayani's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
    Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
    Eur Urol; 2015 Feb; 67(2):e21-2. PubMed ID: 25257031
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Homayoun Zargar, Rafael F. Coelho and Jihad H. Kaouk's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
    Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
    Eur Urol; 2015 Feb; 67(2):e24-5. PubMed ID: 25257032
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
    Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
    Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Marco Borghesi, Gaetano La Manna, and Riccardo Schiavina's Letter to the Editor re: Sabine D. Brookman-May, Matthias May, Ingmar Wolff, et al. Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1-pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA Project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors? Eur Urol 2015;67:943-51.
    Brookman-May S; Shariat SF; May M
    Eur Urol; 2016 May; 69(5):e101-2. PubMed ID: 26388502
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prognostic factors in kidney cancer].
    Patard JJ
    Prog Urol; 2007 Feb; 17(1 Suppl 1):139-43. PubMed ID: 17571637
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Sivaraman A; Barret E
    Eur Urol; 2017 May; 71(5):e148-e149. PubMed ID: 28161029
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.